Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

Candel Therapeutics, Inc. has reported positive final survival data from a phase 2 clinical trial assessing CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC).

The open-label Phase 2 trial enrolled 48 patients in the mITT population with non-resectable locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) across the ...

In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival ...

On January 24, 2008, as part of the 2008 Gastrointestinal Cancers Symposium (Orlando, Florida), a 1-day consensus conference was held on resectable and borderline resectable pancreatic adenocarcinoma.

Prognostic implication of body composition changes in patients with borderline resectable/locally advanced pancreatic adenocarcinoma (PDAC) treated with mFOLFIRINOX. Authors: Jong Hyuk Lee, Hyehyun ...

CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to tumor cells. When administered with a ...

PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC) ...

CAN-2409 - Pancreatic Cancer Positive final survival data from the randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable PDAC demonstrated notable improvement in ...

The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Genes & Diseases. doi.org/10.1016/j.gendis.2024.101490. Currently rated 4.3 by 3 people ...

A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.